Table 2

Efficacy of temozolomide in rhabdomyosarcoma xenograft models

TumorTreatmentNo. in groupAverage week tumor achieved 4× initial tumor volume (1 SD)Tumor growth delay (weeks)Adjusted PaNo. of PRsNo. of CRsMCRbTime to reach nadir (weeks)cTime to recover to initial tumor volume (weeks)d
Rh12cControl42.3 ± 0.500
66696.70.00501012
Rh12cControl54 ± 1.200
667620.0050023
Rh18cControl73.3 ± 0.800
6666 ± 2.12.70.0702012
Rh18cControl63.4 (0.5)00
667(9.3 ± 3.1)5.90.00831023
Rh28Control63.7 ± 1.200
667106.30.00161048
Rh28cControl53.2 ± 0.400
6679.8 ± 2.26.60.02320NRdNR
Rh30Control44.3 ± 1.000
667>12>7.70.0030773>12
Rh66Control74.1 ± 1.100
66710 ± 15.921028
  • a Ps were obtained using exact log-rank tests (with Bonferroni correction procedure). Ps compare tumor failure times among treatment groups and respective control group.

  • b Number of CRs maintained through week 12.

  • c Replicate studies.

  • d NR, no regression.